Curiox BioSystems Co

Curiox BioSystems Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Curiox BioSystems Co (445680.KQ) as of Oct 26, 2026 is -18.27 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -23.49 % — a change of -22.23% (higher).

EBIT/Assets

-18.27 %

YoY

-22.23%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Curiox BioSystems Co is 2023 -18.27 % . Operating Income to Assets Ratio (EBIT/Assets) of Curiox BioSystems Co was 2022 -23.49 % . It decreases by -22.23% higher compared to the previous year.

The Curiox BioSystems Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2021
-14.94 KRW
Jan 1, 2022
-23.49 KRW
Jan 1, 2023
-18.27 KRW
The Curiox BioSystems Co EBIT/Assets history
YEAREBIT/AssetsYoY
-18.27 %-22.23%
-23.49 %+57.19%
-14.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curiox BioSystems Co Stock analysis

What does Curiox BioSystems Co do? Curiox BioSystems Co Ltd generates revenue through the manufacture and sale of automation equipment and consumables for cell analysis processes. The company offers cell pretreatment automation devices, washing machines, and plates, alongside high-capacity adapters, strip spacers, and buffer exchanger products. These products are sold to customers in the Life Sciences Tools & Services industry, primarily within the Korean market. The firm's focus on automation solutions for cell analysis drives its product portfolio and customer base. The company's product lines include cell pretreatment automation devices, washing machines, plates, high-capacity adapters, strip spacers, and buffer exchanger products. These items are designed for use in cell analysis processes, targeting clients who require efficient and precise laboratory equipment. The sales of these specialized tools form the core of Curiox BioSystems' revenue streams. Curiox BioSystems operates within the Life Sciences Tools & Services industry, focusing on providing automation solutions for cell analysis. Its products are manufactured and sold directly to end-users in the life sciences sector, including research institutions and laboratories. The company's revenue is derived from the direct sale of its equipment and consumables without intermediaries. Curiox BioSystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curiox BioSystems Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Curiox BioSystems Co is -18.27 % in 2023.

Operating Income to Assets Ratio (EBIT/Assets) of Curiox BioSystems Co changed from -23.49 % to -18.27 %, representing a -22.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Curiox BioSystems Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Curiox BioSystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Curiox BioSystems Co

All Key Metrics — Curiox BioSystems Co